Showing 261 - 280 results of 79,288 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( a ((non decrease) OR (point decrease)) ))', query time: 0.73s Refine Results
  1. 261

    All data points from Fig 4. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  2. 262

    All data points from Fig 9. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  3. 263

    All data points from Fig 7. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  4. 264

    All data points from Fig 6. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  5. 265
  6. 266
  7. 267
  8. 268

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  9. 269
  10. 270
  11. 271
  12. 272
  13. 273

    Data_Sheet_1_Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity.d... by Chantal C. Clark (10684632)

    Published 2021
    “…</p><p>Conclusion: We observed an association between the use of preexisting thromboprophylaxis and a decreased risk of TE during COVID-19. This suggests that these therapies are beneficial for coping with COVID-19 associated hypercoagulability. …”
  14. 274
  15. 275
  16. 276
  17. 277
  18. 278
  19. 279
  20. 280